April 2017 - Page 93 of 169 -

Dover Tops Q1 Earnings & Revenues, Raises ’17 View

Apr 20, 2017 Jeremy Parkinson Finance 0

Dover Corporation (DOV – Free Report) reported first-quarter 2017 adjusted earnings per share from continuing operations of 70 cents, which increased 25% from 56 cents recorded in the prior-year quarter. Earnings also beat the Zacks Consensus Estimate of 62 cents. Including one-time items, earnings came in at $1.09 per share, up from the prior-year figure of $0.64. Total […]

ETFs Are Reducing Market Efficiency

Apr 20, 2017 Jeremy Parkinson Finance 0

ETFs have attracted plenty of criticism over the past few years, and according to researchers at Stanford University, Emory University and the Interdisciplinary Center of Herzliya in Israel, at least some of these concerns are valid. The researchers published a paper on the topic last month within which they examined whether an increase in ETF ownership is accompanied by […]

Leading Economic Indicators: More Soft Data Silliness

Apr 20, 2017 Jeremy Parkinson Finance 0

The index of leading economic indicators rose by 0.4% beating the Econoday Consensus estimate of 0.2%. “Gains were broad-based in the month led by the ISM new orders index and including, as always, the interest rate spread where short-term rates are unusually low. The LEI has been very solid and continues to point ahead to rising economic […]

Hot Options Report For Midday – Thursday, April 20

Apr 20, 2017 Jeremy Parkinson Finance 0

Most Active Stock Options For Midday April 20, 2017

Continuing Jobless Claims Collapse To Lowest Since Right Before DotCom Crash Began

Apr 20, 2017 Jeremy Parkinson Finance 0

The last time continuing jobless claims was this low, the Nasdaq peaked at the end of the dotcom boom and collapsed over 80% in the next 2 years. So be careful what you crow about… The ‘best’ continuing jobless claims print since April 2000… tumbling to 1.979 million (well below the 2.024 million expectations) Despite a […]

March Inflation, Retail Sales And Gold

Apr 20, 2017 Jeremy Parkinson Finance 0

Last week, two important U.S. economic reports were released. What do they imply for the gold market? Recently, geopolitical events – such as the U.S. strike in Syria, tensions over the North Korea, Turkish constitutional referendum, or May’s call for a snap election in the UK – have caught the investors’ attention. However, geopolitical events rarely lead to lasting rallies. Since the […]

EC How The Passive Investing Mania Undermined Its Most Basic Assumption

Apr 20, 2017 Jeremy Parkinson Finance 0

I have argued that “passive investing” is an oxymoron because it denies precisely that which defines an investment: active analysis. Proponents of the strategy don’t seem worried about this inconsistency, though. This is likely due to the fact that most of them believe the market to be, to a great extent, efficient. From Wikipedia: Efficient-market hypothesis (EMH) is a […]

REIT Dividend Matchup: Realty Income Vs. Omega Healthcare Investors

Apr 20, 2017 Jeremy Parkinson Finance 0

Real Estate Investment Trusts, or REITs as they are more commonly known, are a great source of income. It is not uncommon to find REITs with dividend yields that are several percentage points above the S&P 500 average, which hovers around 2% right now. Realty Income (O) and Omega Healthcare Investors (OHI) are no different. […]

BNY Mellon’s Q1 Earnings & Revenues Meet Expectations

Apr 20, 2017 Jeremy Parkinson Finance 0

The Bank of New York Mellon Corporation’s (BK – Free Report) first-quarter 2017 adjusted earnings per share were 80 cents, in line with the Zacks Consensus Estimate. A rise in revenues and provision benefit supported the results. Also, assets under management (AUM) reflected growth. However, a marginal increase in expenses and lower foreign exchange and other trading […]

Tesaro Drops After Zejula Pricing, Competing PARPi Trial Miss

Apr 20, 2017 Jeremy Parkinson Finance 0

The shares of drug maker Tesaro (TSRO) are falling with two possible headwinds cited by analysts as the potential culprit, namely the pricing of its niraparib treatment and the disappointing trial results of another drug in the same therapeutic space. PRICING: Last night, Tesaro announced that Zejula, its oral, once-daily poly polymerase inhibitor, is now […]